Laboratory biomarkers can provide valuable confirmation in cases where clinical diagnosis proves challenging.
The diagnosis of anaphylaxis can be tricky, especially in the absence of known triggers and when other conditions, such as urticaria and asthma, mimic aspects of the reaction. Biomarker s can help to identify this deadly condition promptly.
But only histamine and tryptase have been extensively studied. Tryptase is the most frequently used biomarker for diagnosing anaphylaxis, but it is not the most reliable in minimizing false-positive or negative results. A more accurate approach to using tryptase requires clinicians to have the patient’s baseline level on hand, according to a new systematic review published in“There are so many other biomarkers that could maybe help us diagnose anaphylaxis with better accuracy,” said Roy Khalaf, MD, a resident in the Faculty of Medicine at McGill University in Montreal, Quebec, Canada, and a lead author of the study. Khalaf and his colleagues analyzed 28 studies published over a 20-year period starting in 2004 on biomarkers of anaphylaxis, with a sample of more than 18,000 patients, 3329 of whom had confirmed anaphylaxis. While tryptase was the most studied biomarker, its ability to correctly identify patients who have the disease, or sensitivity, was suboptimal at 0.49. However, its specificity, or ability to identify those who did not have the disease, was 0.82. When a baseline level of tryptase was compared with a level drawn during anaphylaxis, the sensitivity improved to 0.78. Many patients do not have their baseline levels unless they have seen an allergist. One study indicated that combining histamine with tryptase boosted the sensitivity to 0.93. Histamine alone showed higher sensitivity but lower specificity . The use of histamine is also limited by its short half-life of about 15 minutes. One study in the review of a rarely used biomarker, platelet-activating factor , showed great promise , but Khalaf said more data are needed before the test can be used clinically. Limited data on PAF acetylhydrolase and urinary prostaglandin D2 were available. Urinary prostaglandin D2 has shown promise, but “there may be practical challenges in obtaining urine samples from patients experiencing life-threatening reactions,” Khalaf and his colleagues wrote. Inflammatory chemicals like tryptase and prostaglandins are triggered by a reaction caused by allergens or environmental factors like exercise. These mediators can cause vasodilation, smooth muscle contraction, and increased vascular permeability, resulting in bronchoconstriction, airway swelling, and death. If found early, anaphylaxis can be reversed with the use of epinephrine. “If you already have a confirmed diagnosis of anaphylaxis, you can anticipate the next reaction and act appropriately,” Khalaf toldEstablishing a definitive diagnosis is instrumental to preventing another occurrence. Khalaf said he hopes more clinicians, especially in emergency settings, will test for biomarkers to confirm anaphylaxis, especially in diagnostically challenging situations or when a clinician is unfamiliar with the condition. Patients with anaphylaxis must be monitored for a few hours after the event to prevent a flare-up of the condition. Patients with confirmed anaphylaxis should also receive a prescription for an epinephrine auto-injector. Clinicians should also make a referral to an allergist to determine triggers, especially considering epinephrine auto-injectors can be costly, said Jason Caldwell, DO, an allergy and immunology specialist at the Medical University of South Carolina in Charleston, South Carolina. Additionally, allergists routinely order biomarker tests. While tryptase and histamine are readily available, the other biomarkers are largely only accessible in urban hospital settings, Caldwell said. Tryptase sensitivity is enhanced when a clinician knows baseline levels, but few patients have this information when they arrive at the emergency department. Primary care clinicians and pediatricians generally do not order these tests for patients with allergies who have not had the reaction. With more comprehensive studies, researchers could establish protocols and improve patient outcomes, Khalaf said. Clinicians also need new biomarkers because those currently available do not cover every trigger, Caldwell said.The authors of the review reported no relevant financial disclosures.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Biomarker Biological Marker Multi-Biomarker Disease Activity MBDA Multibiomarker Disease Activity Asthma Asthmatic Histamine Allergy Prostaglandins Immunology South Carolina Urticaria And Angioedema Urticaria And Angio-Oedema Airway Airway Management Management Of The Airway Allergens Bronchoconstriction Canada Canadian Exercise Physical Activity Hands Hospitals Muscles
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The most reliable used cars to buy, as auto tariffs take effectEmily Hanford-Ostmann is an Emmy-nominated producer and graduate of the E.W. Scripps School of Journalism at Ohio University.
Read more »
Trump is expected to sign executive orders to boost coal, a reliable but polluting energy sourcePresident Donald Trump is expected to sign executive orders aimed at boosting coal, a reliable but polluting energy source that’s long been in decline.
Read more »
Trump expected to sign executive orders to boost coal, a reliable but polluting energy sourcePresident Donald Trump is expected to sign executive orders aimed at boosting coal, a reliable but polluting energy source that’s long been in decline. Two senior White House officials say Trump will use his emergency authority to allow some older coal-fired power plants set for retirement to keep producing electricity to meet rising U.S.
Read more »
Trump is expected to sign executive orders to boost coal, a reliable but polluting energy sourcePresident Donald Trump is expected to sign executive orders aimed at boosting coal, a reliable but polluting energy source that’s long been in decline.
Read more »
Trump signs executive orders to boost coal, a reliable but polluting energy sourceTrump also directed federal agencies to identify coal resources on federal lands, lift barriers to coal mining and prioritize coal leasing on U.S. lands.
Read more »
Trump signs executive orders to boost coal, a reliable but polluting energy sourceThe orders direct agencies to lift barriers to coal mining and prioritize coal leasing on federal lands, and end Obama-era moratoriums.
Read more »